I've been watching RAC for a few years. The company and posters here staunchly backed the IP protection and commercial viability of RC110.
It's amazing to see the about-turn on this, and investors still seem happy enough. After all this time the company admits RC110 is commercially redundant.
I suppose it means they are feeling supremely confident in the pre-clinical data for RC220 so far. But that's where RAC is now, back to a pre-clinical company.
Ann: Updated Strategy and Investor Presentation, page-223
-
- There are more pages in this discussion • 286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |